Dysregulation of MS4A3 and PRDX5 gene expression in multiple myeloma patients
Hindilerden, Ipek Yonal
Ekmekci, Sema Sirma
MetadataShow full item record
CitationIlknur, S. U. E. R., Aynur, A. D. A. Y., SARIMAN, M., Mesut, A. Y. E. R., HINDILERDEN, I. Y., EKMEKCI, S. S., ... & OZTURK, S. Dysregulation of MS4A3 and PRDX5 Gene Expression in Multiple Myeloma Patients. International Journal of Hematology and Oncology, 31(4), 205-213.
Multiple myeloma (MM) is a disease in which plasma cells increase clonally. We aimed to investigate the comparison of our transcriptome data in MM, MGUS (Monoclonal gammopathy of undetermined significance) and control groups in our research. Analysis of transcriptome data revealed that CD74, FUS, MS4A3, PTPN6, PRDX5 and UNC45B genes were significantly different in the MM group compared to control group. Pathway analyzes of these genes have shown that they are associated with certain pathways such as the cellular response and immunological system. In this study, we aimed to examine the expression levels of these genes among the MM (n=50), MGUS (n=15) and control (n=14) groups using the Quantitative Real-Time Polymerase Chain Reaction. According to the consequence of the study, it was determined that MS4A3 gene expression decreased significantly in the MM patient group compared to MGUS and control group, while PRDX5 gene expression was significantly increased. Also ROC (Receiver Operating Characteristic) analysis showed that MS4A3 gene has a significant diagnostic power between MM and MGUS group (area=0.727; p=0.008). Since multiple myeloma is more common in men than in women, it was statistically evaluated whether there is no difference in gene expression between women and men. However, it was determined that there was no statistically significant difference between the groups. As a result, the MS4A3 and PRDX5 genes, which are important in various diseases such as cancer, may shed light on new treatment options for MM disease.